Blood screening for preclinical Alzheimer’s disease in a British birth cohort

Takeaway

  • In a theoretical cohort prevalence range of 10–50% amyloid positron emission tomography (PET) positivity, mass spectrometry amyloid-β1–42/1–40 measures would consistently reduce numbers of individuals proceeding to scans, showing greater efficiency and reduced cost.

Why this matters

  • Advances in Alzheimer’s disease (AD) research have yielded multiple potential blood-based detection techniques for the AD marker, amyloid-β during the preclinical disease stage; however, findings regarding their efficiency have been mixed.

  • The efficiency of liquid chromatography-mass spectrometry (LC-MS) for identifying plasma AD markers may lead to increased screening and identification of individuals at risk of developing clinical AD, resulting in significant time and cost saving, whilst allowing earlier intervention for at-risk populations.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.